Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
voruciclib + venetoclax
- Development stage
- Unknown
- Lead developer
- MEI Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Voruciclib + venetoclax is an investigational combination therapy being studied primarily for relapsed or refractory acute myeloid leukemia (AML) and B-cell malignancies. Voruciclib is an orally administered, selective cyclin-dependent kinase 9 (CDK9) inhibitor that downregulates anti-apoptotic proteins such as Mcl-1 and c-Myc, which are implicated in resistance to apoptosis in cancer cells. Venetoclax is a selective B-cell lymphoma 2 (Bcl-2) inhibitor approved for the treatment of chronic lymphocytic leukemia and AML. The rationale for combining these agents stems from preclinical evidence showing that CDK9 inhibition by voruciclib can overcome resistance to venetoclax by suppressing Mcl-1 expression, thereby enhancing apoptosis in leukemic cells. Early-phase clinical studies have demonstrated that this combination has synergistic antileukemic activity with manageable toxicity profiles in heavily pretreated patients with AML[1][4][5][6][8].
- Other names
- voruciclib + venetoclax
02
Targets
BCL-2 (BCL-2 family)CDK9 (Cyclin-dependent kinase 9)
Beyond the preview
Go deeper on voruciclib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on voruciclib + venetoclax.